Corporate

Presentation
J. B Chemicals & Pharmaceuticals +91-22-30451200 | corporate@jbcpl.com
www.jbcpl.com
Corporate
Presentation
J.B. Chemicals & Pharmaceuticals
www.jbcpl.com
2
J. B. Chemicals & Pharmaceuticals Ltd.
Forward Looking Statements
In this presentation we have disclosed forward looking information to enable
investors to comprehend our prospects and take informed investment decisions.
This presentation and other statements, written and oral, that we periodically make
contain forward looking statements that set out anticipated results based on the
managements plan and assumptions.
We have tried wherever possible to identify such statements by using words such
as anticipate, aims estimate, expects, project, intends, plans,
believes, and words of similar substance in connection with any discussion of
future performance. We cannot guarantee that these forward looking statements
will be realized, although we believe we have been prudent in assumptions.
The achievement of results is subject to risks, uncertainties and even inaccurate
assumptions. Should known or unknown risks or uncertainties materialize or
should underlying assumptions prove inaccurate, actual results could vary
materially from those anticipated, estimated or projected. Everybody should bear
this in mind.
3
J. B. Chemicals & Pharmaceuticals Ltd.
COMPANY
BUSINESS UNITS
MANUFACTURING
STRATEGY
4
J. B. Chemicals & Pharmaceuticals Ltd.
The name J. B. Chemicals & Pharmaceuticals Ltd. was
christened after Mr. J. B. Mody who is the Chairman and
founder of JBCPL
JBCPL is a leading and publicly traded pharmaceutical
company in India
Leading by the vision and dynamism of Mr. J. B. Mody, a
visionary and pioneer with an experience of over five
decades in the pharmaceutical industry, the group has
diversified into different sectors



Background
5
J. B. Chemicals & Pharmaceuticals Ltd.
Incorporated in 1976 with an IPO in 1985
Listed on the BSE and NSE with a market cap of USD 110
million
7 manufacturing sites in Gujarat and Maharashtra for
formulations and API
1 R&D centre
Subsidiary in South Africa and Russia
Total employee strength of 2900

Brief on JBCPL
6
J. B. Chemicals & Pharmaceuticals Ltd.
Annual Revenues & Profits










R
s
.

i
n

c
r
o
r
e
s

SALES PAT
2008-09 723 79
2009-10 670 101
2010-11 786 118
2011-12* 636 47
723
79
670
101
786
118
636
47
0
100
200
300
400
500
600
700
800
900
* Divestment of Russia-CIS OTC business to J&J
7
J. B. Chemicals & Pharmaceuticals Ltd.
Annual Revenues & Profits










U
S
D

i
n

m
i
l
l
i
o
n
s

SALES PAT
2008-09 162 17
2009-10 171 26.4
2010-11 187 31.1
2011-12* 129 9.4
162
17
171
26.4
187
31.1
129
9.4
0
20
40
60
80
100
120
140
160
180
200
* Divestment of Russia-CIS OTC business to J&J
8
J. B. Chemicals & Pharmaceuticals Ltd.
Strategic Business Units





JBCPL
INDIA
41%
CONTRAST
MEDIA
5%
GLOBAL
26%
API
6%
RUSSIA &
CIS
22%
BUSINESS
DEVELOPMENT
Prescription and Hospital
INDIA
CONTRAST MEDIA
ANDA
Contract Manufacturing
Branded Generics
OTC
Contrast Media
GLOBAL
API
Contract Manufacturing
Prescription and Hospital
RUSSIA & CIS
9
J. B. Chemicals & Pharmaceuticals Ltd.
India
Prescription products
Domestic market estimated at about USD 11 billion and
growing by about 18% as per ORG

JBCPL Ranked 36
th
(ORG) with 3 brands featuring in top
300 brands reported by ORG

JBCPL continued consolidation process during 2011-12,
and adopted key brands focus marketing strategy.




10
J. B. Chemicals & Pharmaceuticals Ltd.
India
Top 4 therapeutic segments: Gastro-enterology,
Cardiovascular, Pain management and Antibiotic

Acute segment contributes about 82% of total sales

Current field force: 1100 sales representatives
11
J. B. Chemicals & Pharmaceuticals Ltd.
India
Growth Plan
JBCPL has placed increased concentration on domestic
market for next level growth.
Increase in field force
New product introductions
JBCPL plans to increase field force to 1500 in 2012-13.
This is aimed at strengthening rural market presence
with strength increase in urban market too




12
J. B. Chemicals & Pharmaceuticals Ltd.
Contrast Media niche focus
Contrast Media Products
Caters to niche radio-diagnostic products used in CT Scan, MRI
and Cath Lab through 30 sales representatives
Iopamidol
Iohexol
Gadopentetate dimeglumine
Diatrizoate Meglumine
In-licensed a new Ultrasound Contrast Imagining product
(Definity) of Lantheus Medical Imaging Inc. from USA





13
J. B. Chemicals & Pharmaceuticals Ltd.
Russia/Ukraine/CIS

Kazakhstan
Kyrghyztan
Uzbekistan
Tajikistan
Turkmenistan
Azerbaijan
Armenia
Georgia

Mald
ova
Ukraine
Byelorussia
Lithuania
Latvia
Estonia
Russia
Mongolia
14
J. B. Chemicals & Pharmaceuticals Ltd.
Russia/Ukraine/CIS
Russia is one of the most potential markets
Russian market is estimated to be about US $12
billion at retail level, growing by about 7% in value
annually
JBCPL is ranked amongst the top Indian companies
Entered Russia in 1992
Offices in Russia/Ukraine and some CIS countries

15
J. B. Chemicals & Pharmaceuticals Ltd.
Russia/Ukraine/CIS

Divested OTC portfolio to Johnson & Johnson in
May 2011
Contract manufacturing for J&J for these OTC
products
Prescription business continues through wholly
owned subsidiary in Russia
16
J. B. Chemicals & Pharmaceuticals Ltd.
Global
Contract Manufacturing and Product pipeline will increase to fuel growth


Activity wise breakup
17
J. B. Chemicals & Pharmaceuticals Ltd.
Global

Top markets breakup
18
J. B. Chemicals & Pharmaceuticals Ltd.
South Africa
In 2007, JBCPL has made strategic investment in
Biotech Laboratories (Pty) Ltd., South Africa, a BEE
marketing and sales, marketing and distribution
company
Have 49% equity stake with preference shares to take
it to 51%
Robust products pipeline to strengthen direct
business with Biotech
19
J. B. Chemicals & Pharmaceuticals Ltd.
Contract Manufacturing (Clear Focus)





Projects awarded by multinationals globally
More than 10 clients
Tailor made services for customers



Contract Manufacturing
Injectables
Vials
Ampoules
Form Fill Sealed


Semi-solid
Creams
Ointments
Gels
Solid
Tablets
Lozenges
Herbal
Medicated
20
J. B. Chemicals & Pharmaceuticals Ltd.
Complete package
New Product development
Analytics services
Technology transfer
Regulatory support
Manufacturing



Contract Manufacturing
21
J. B. Chemicals & Pharmaceuticals Ltd.
Lozenges, a JBCPL niche strength, has excellent
scope in global market
Medicated and Herbal
We manufacture lozenges under our own brands
and private label
Private label lozenges for leading UK/EU, South
African, Australian and Canadian companies.


Lozenges
22
J. B. Chemicals & Pharmaceuticals Ltd.
JBCPL manufactures 2 APIs
one of the largest manufacturer of Diclofenac
Sodium (BP, EP, USP) and Nifedipine



API Business
23
J. B. Chemicals & Pharmaceuticals Ltd.
Brands | Assets
Zecuf herbal Cough and Cold
Nicardia (Nifedipine) Anti-hypertensive
Metrogyl (Metronidazole) Anaerobicide
Rantac (Ranitidine) Anti-peptic ulcerant
Panum (Pantaprazole) Anti-peptic ulcerant
OF (Ofloxacin) Antibiotic
Dicloran (Diclofenac
Sodium)
NSAID
24
J. B. Chemicals & Pharmaceuticals Ltd.
At Daman
Located at Kadaiya, Daman
Manufactures lozenges and tablets
Lozenges approved by:
UK MHRA
TGA Australia
MCC South Africa
FDB Ghana
Manufacturing Facilities
25
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant TI 10
Located at Panoli
Manufactures tablets
Facility approved by
US FDA
UK MHRA
TGA Australia
MCC South Africa
INVIMA Colombia
Germany (EU-GMP)
Manufacturing Facilities
26
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant IV -17
Located at Panoli
Manufactures injectables -
FFS, vials and ampoules
Facility approved by:
MCC South Africa
INVIMA Colombia


Manufacturing Facilities
27
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant IV -14
Located at Panoli
Manufactures injectables,
ointments & cold rubs
Facility approved by:
MCC South Africa
NDA Uganda
Pharmacy Board Tanzania
INVIMA Colombia
Manufacturing Facilities
28
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant L-6
Located at Panoli
Manufactures herbal liquids
Manufacturing Facilities
29
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant D 9
Located at Panoli
Manufactures Diclofenac API
Facility approved by:
US FDA
Germany EU-GMP
Manufacturing Facilities
30
J. B. Chemicals & Pharmaceuticals Ltd.
At Gujarat
Plant UM 12
Located at Ankleshwar
Manufactures tablets and liquids
Facility approved by:
NDA - Uganda (Tablets & liquids)
Pharmacy Board - Tanzania (liquid)
Manufacturing Facilities
31
J. B. Chemicals & Pharmaceuticals Ltd.
Strategy
ANDA: Develop and manufacture products for USA market
Contract Manufacturing: Increase our customer base by providing
quality products at cost effective prices
Russia marketing: Form JV/Partnerships for marketing
New Territories: Expand into newer territories through partnerships
Capacities: Enhance capacities in 2012-13 for ANDA and contract
manufacturing
tablets
Injectables
Lozenges


Thank You
J. B Chemicals & Pharmaceuticals
+91-22-30451200 | corporate@jbcpl.com
www.jbcpl.com